Immutep Halts Pivotal Lung Cancer Trial for Futility – Analysts Issue Sharp Downgrades

Immutep’s key Phase 3 trial for its cancer drug efti was stopped early due to poor results. Analysts from Citizens and Baird downgraded the stock.